EMYIF yields 16.13% · PFE yields 6.13%● Live data
📍 EMYIF pulled ahead of the other in Year 1
Combined, EMYIF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EMYIF + PFE for your $10,000?
Euromoney Institutional Investor PLC, together with its subsidiaries, provides business-to-business information services in the United Kingdom, North America, and internationally. The company operates through three segments: Fast Markets, Financial & Professional Services, and Asset Management. The Fast Market segment provides commodity price benchmarks and analysis to its clients' business processes and workflows in the metals, mining, forest products, and agriculture industries. The Financial & Professional Services segment offers actionable data, market and people intelligence, accreditation, marketing, and event services to financial and professional services businesses. The Asset Management segment provides independent research that enables its customers to make informed investment decisions; runs networks and conferences that bring asset allocators and managers together; and offers news and data for the industry to stay informed and make deals. It also engages in the research and data service, publishing, property holding activities. The company was formerly known as Euromoney Publications PLC and changed its name to Euromoney Institutional Investor PLC in April 1999. The company was incorporated in 1969 and is headquartered in London, the United Kingdom. As of November 24, 2022, Euromoney Institutional Investor PLC was taken private.
Full EMYIF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.